Opko Health, Inc.
4400 Biscayne Boulevard
266 articles with Opko Health, Inc.
OPKO Health Reports 2019 Fourth Quarter Business Highlights and Financial ResultsConference call begins at 4:30 p.m. Eastern time today
OPKO Health, Inc. reports business highlights and financial results for the three months ended December 31, 2019..
MIAMI, Feb. 20, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2019, as well as provide guidance on expected revenues and operating expenses for the first quarter and full year 2020, after the close of the U.S. financial markets on Wednesday, February 26, 2020. OPKO’s senior management will provide a business update and discuss its financial results in a live conference call and audio webcast
OPKO Health, Inc. announced that management will be participating in the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020 at the Westin St. Francis in San Francisco.
OPKO Health Reports 2019 Third Quarter Business Highlights and Financial ResultsConference call begins at 4:30 p.m. Eastern time today
OPKO Health, Inc. reports business highlights and financial results for the three months ended September 30, 2019..
OPKO Health, Inc. (NASDAQ: OPK) plans to report its operating and financial results for the three months ended September 30, 2019, as well as provide guidance on expected revenues and operating expenses for the third quarter 2019, after the close of the U.S. financial markets on Tuesday, November 5, 2019.
The offering is expected to close on or about October 29, 2019, subject to customary closing conditions.
OPKO Health, Inc. announced that, subject to market and other conditions, it intends to offer and sell up to $100 million of shares of its common stock in an underwritten public offering.
Johnson Fistel, LLP Announces Investigations of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. and Uxin Limited; Investors Encouraged to Contact Firm
Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims.
Rosen Law Firm Reminds OPKO Health, Inc. Investors of Important Deadline in First Filed Case by Firm - OPK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of OPKO Health, Inc. from September 26, 2013 through September 7, 2018, inclusive (the "Class Period") of the important November 13, 2018 lead plaintiff deadline in the first filed case commenced by the Rosen Firm. The lawsuit seeks to recover damages for OPKO investors under the federal securities laws.
OPK LOSS NOTICE ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against OPKO Health, Inc.; Important Deadline - OPK
Rosen Law Firm announces it has filed a class action lawsuit on behalf of purchasers of the securities of OPKO Health, Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OPKO Health - OPK
Pomerantz LLP is investigating claims on behalf of investors of OPKO Health
OPKO Class Action: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against OPKO Health, Inc. - OPK
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of OPKO Health, Inc.
OPKO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In OPKO Health To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against OPKO Health, Inc.
OPKO is working expeditiously to respond to Nasdaq’s request for information, but it cannot currently estimate when trading will resume.
OPKO Health, Inc. provided the following comment on the lawsuit filed by the U.S. Securities and Exchange Commission earlier today.
OPKO Health’s fourth-quarter report highlighted positive activities in the face of a net loss of $213.9 million during the most recent quarter.
The Company has begun a search for his replacement and, in the interim, a committee of senior management will assume operational responsibilities.
The deal is aimed at identifying novel genes and pathways to help manage human genetic diseases.
OPKO Health Enrolls First Patient in Phase IIB Study of OPK88004 to Treat Benign Prostatic Hypertrophy
Enlarged prostate affects approximately 50 million men in the U.S.
OPKO’s senior management will provide a business update and discuss results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time today.